Literature DB >> 17984356

Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig.

Anthony A Fossa1, Todd Wisialowski, J Neil Duncan, Shibing Deng, Michael Dunne.   

Abstract

Prolongation of the electrocardiogram QT interval by some, but not all drugs, has been associated with increased incidence of sudden cardiac death. Current preclinical regulatory assays cannot discriminate the arrhythmia liability of these drugs. Consequently, many new medications that prolong the QT interval are not developed despite their potential therapeutic benefit. Alternans (action potential duration alternations) is a measure of cardiac instability in humans and animals associated with the onset of ventricular fibrillation. Due to potential arrhythmia risk from observed QT prolongation, alternans was assessed in the anesthetized guinea pig after azithromycin or chloroquine alone and after combination treatment at clinically relevant concentrations proposed for the management of malaria. Chloroquine alone, but not azithromycin, caused a profound increase in action potential duration but with only minimal effects on alternans (approximately 10 ms). Azithromycin alone and in combination with chloroquine showed no increase in alternans beyond vehicle baseline responses indicating no additional arrhythmia liability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984356

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

Review 1.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

2.  Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint.

Authors:  Sayak Roy
Journal:  SN Compr Clin Med       Date:  2020-06-27

3.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

4.  Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.

Authors:  Brioni R Moore; John M Benjamin; Siu On Auyeung; Sam Salman; Gumul Yadi; Suzanne Griffin; Madhu Page-Sharp; Kevin T Batty; Peter M Siba; Ivo Mueller; Stephen J Rogerson; Timothy Me Davis
Journal:  Br J Clin Pharmacol       Date:  2016-03-27       Impact factor: 4.335

Review 5.  Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.

Authors:  R Matthew Chico; Daniel Chandramohan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-07-07       Impact factor: 4.481

6.  Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria.

Authors:  Tiphaine Gaillard; Jérôme Dormoi; Marylin Madamet; Bruno Pradines
Journal:  Malar J       Date:  2016-02-12       Impact factor: 2.979

Review 7.  Cardiac effects and toxicity of chloroquine: a short update.

Authors:  Kanigula Mubagwa
Journal:  Int J Antimicrob Agents       Date:  2020-06-19       Impact factor: 5.283

Review 8.  An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.

Authors:  Dragana Javorac; Lazar Grahovac; Luka Manić; Nikola Stojilković; Milena Anđelković; Zorica Bulat; Danijela Đukić-Ćosić; Marijana Curcic; Aleksandra Buha Djordjevic
Journal:  Food Chem Toxicol       Date:  2020-07-21       Impact factor: 6.023

9.  Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.

Authors:  Hartmut Derendorf
Journal:  Int J Antimicrob Agents       Date:  2020-05-07       Impact factor: 5.283

Review 10.  Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Authors:  Janet Sultana; Paola Maria Cutroneo; Salvatore Crisafulli; Gabriele Puglisi; Gaetano Caramori; Gianluca Trifirò
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.